Thank you, Marcus. Let's now turn our attention to Slide 10, where I'll outline our key initiatives for 2024. Our top priority for the New Year is to refinance the 2026 senior notes before they go current in January 2025. To best position us to execute on this refinancing, we will continue to prioritize debt reduction. We are targeting a gross debt reduction of $70 million in 2024, financed through business generated free cash flows and a potential monetization of $35 million to $40 million in passive assets. Additionally, as announced last year, we are exploring the potential sale of our profitable Paperboard and high-yield pulp businesses to further reduce the debt before the refinancing. This sales process is being managed by Houlihan Lokey, and it remains on schedule. We received expressions of interest from both strategic parties and financial sponsors, and we'll provide further updates on this project as it develops. We are working hard to implement our asset optimization strategies to address our HPC commodity exposure given the drag this exposure has on our profit margins and earnings stability. To highlight the importance of this effort, our non-fluff commodity sales had an EBITDA loss of minus $60 million in 2023. And currently, we project a minus $48 million EBITDA loss in 2024. Obviously, it's a strategic imperative to mitigate this exposure to non-fluff commodities. As you know, a key element of our strategy entails transferring a significant portion of our viscose production to our Temiscaming HPC facility, which benefits from the lowest variable cost among our HPC lines. I'm pleased to announce the project is progressing according to our initial time line, and I will provide updates as we move forward. Our final and perhaps most compelling initiative is to continue realizing the exceptional opportunities within our biomaterials business. Our Tartas bioethanol plant is currently going through testing. And if all goes well, we expect to begin bioethanol production in March. This project is expected to generate $4 million in EBITDA this year as we ramp up production and then $8 million to $10 million in 2025 and thereafter when we achieve steady-state production. This project is the first of several biomaterial projects that we plan to launch over the next couple of years. As highlighted during our Investor Day, upcoming projects in the pipeline include a bioethanol plant at our Fernandina facility, the AGE project at our Jesup facility, which is the production of green energy for sale to Georgia Power, a prebiotics additive plant to also be located at our Jesup facility and crude tall oil projects in France and in the U.S. As previously disclosed, these projects will primarily be funded by low-cost green project capital and are expected to generate significant margin expansion due to co-product economics and economies of scale. Last night, we announced an MOU with Verso Energy to explore e-fuels, specifically e-SAF from renewable resources, including biogenic CO2 at our Tartas plant, SAF or Sustainable Aviation Fuel would be used by the global airline industry as a drop in sustainable replacement for current Jet Fuel. We'll be working with Verso Energy to explore the feasibility of capturing the biogenic CO2 produced at the Tartas plant to produce the e-SAF in combination with green hydrogen. While we are still in the early stages of evaluating this opportunity, the potential impact to RYAM is substantial. We look forward to keeping you updated as this project progresses. Let's move to Slide 11, where I'll present our EBITDA and free cash flow projections for 2024. We anticipate 2024 enterprise EBITDA to range between $180 million and $200 million for the year. Cash interest expense is expected to be in the $85 million range, which is inclusive of $14 million attributed to the timing of interest payments. On a normalized basis, the estimated annual interest expense would be around $70 million. Maintenance expense is set at $85 million, a figure we consider sufficient this year to maintain the reliability of our assets. We project a $15 million benefit from working capital, an additional $10 million benefit from tax receivables to be realized during the year. With some offsets related to deferred energy payments and other accrued liabilities, we expect adjusted free cash flow to range between $20 million to $40 million for the year, which will be used to reduce debt and invest in strategic capital projects. Currently, we forecast such strategic CapEx spending of around $10 million in 2024, mainly to finance the ERP project and pursue high-return cost reduction projects at the plants. This guidance differs from the $225 million EBITDA estimate that I presented during the Investor Day, I believe it's important to emphasize the factors driving this experience. Since the Investor Day guidance, we realized a $14 million decrease in Paperboard EBITDA versus expectations due to unforeseen levels of destocking towards the end of the year. High-yield pulp experienced rapid price declines post Investor Day as pulp market has encountered weak demand, resulting in a $3 million impact versus expectations. We also now expect destocking at a couple of large acetate customers, which will impact EBITDA by $23 million in 2024. Additionally, corporate charges were primarily affected by higher discounting and financing fees, encouraged to support working capital enhancements due in part to higher interest rates totaling approximately $5 million. On Slide 12, I delve deeper into the expected performance of each of our businesses. For 2024, we expect to achieve EBITDA in the range of $180 million to $190 million for our HPC segment. On average, Cellulose Specialty prices are expected to increase a low single-digit percentage as compared to 2023. Cellulose Specialty sales prices are expected to remain flat in 2024 with increased volumes from market share gain that accrued to us from a competitor's plant closure, offset principally by lower shipments due to the stocking to select acetate customers. Demand for RYAM Cellulose Specialties is anticipated to be mixed with improved volumes in construction ethers albeit at lower than historical levels and relatively stable acetate markets. However, as noted, we expect acetate will undergo some level of destocking. We also anticipate strong demand in the other CS grades. Additionally, we expect resilient market demand for commodity products, the fluff and viscose price is expected to improve from Q4 2023. Moreover, we foresee modest tailwinds from eased raw material and logistics input costs in 2024. As part of our growth strategy, we are actively pursuing strategic investments in our biomaterials business to capitalize on the increasing demand for sustainable products. The Tartas bioethanol plant is set to begin commercial production in the first quarter of this year with an expected EBITDA contribution of $4 million in 2024, which is expected to reach $8 million to $10 million upon full production that is expected in 2025. Regarding Paperboard, we expect to achieve EBITDA in the range of $50 million to $60 million in 2024. Prices are expected to decrease slightly as compared to 2023 Q4 levels, while sales volumes are expected to improve as destocking eases and production scales up to meet the improved demand. Raw material prices are expected to see a slight uptick as pulp markets rebound. We expect to achieve EBITDA in the range of $5 million to $10 million in 2024 for our high-yield pulp business. High-yield pulp prices are expected to increase in the first quarter as we realized higher index pricing observed in the later part of 2023 Q4. However, we are beginning to see pricing pressure related to the Chinese pulp markets, thus expect pricing pressure in late Q2 and possibly Q3. We are diversifying our portfolio globally to mitigate this exposure. Additionally, sales volumes are projected to improve in Q1 as production ramps up to meet improved customer demand. For 2024, we expect corporate costs in the range of $55 million to $60 million, flat to up slightly versus 2023 as we are in the final year of our multiyear ERP implementation. As the ERP project concludes, we anticipate annual cost reductions of $3 million to $5 million starting in 2025. It's important to note that these costs may vary due to factors like currency fluctuations, environmental charges and other non-cash expenses. We illustrate the trajectory of our EBITDA margin growth and net leverage decline on Page 13. In 2024, we anticipate our margins to be in the 10% to 11% range, reflecting a weighted average of the strong margins in our Cellulose Specialty and Paperboard segments, counterbalanced by a low positive high-yield margins and the anticipated negative margins in our non-fluff commodity sales. The forecast for net secured leverage at the end of the year stands at 3.3 times covenant EBITDA. Our commitment remains resolute in achieving our target net debt leverage ratio of 2.5 times by 2027. With that, operator, please open the call to questions.